Zai Lab (ZLAB) President and Chief Operating Officer Josh Smiley will leave the company effective May 22 as part of changes to its senior leadership team, the company said Friday.
The company expects several 2026 milestones, including zoci data in small cell lung cancer and neuroendocrine carcinomas, as well as initial Phase 1/1b data for ZL-1503, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments